Pfizer Inc. (NYSE:PFE)

The financial performance, as indicated by the income statement, exhibits considerable fluctuation over the analyzed period from April 2021 to December 2025. Revenues initially demonstrated strong growth, peaking in the July 2022 period, before experiencing a decline and subsequent stabilization with moderate growth in later periods. A significant shift in revenue composition is also apparent, with a growing reliance on alliance and royalty revenues alongside product revenues.

Revenue Trends

Revenues began at US$14.516 billion in April 2021 and increased substantially to US$27.742 billion by July 2022. Following this peak, revenues decreased to US$17.763 billion by December 2022, and then fluctuated between US$13.715 billion and US$17.557 billion through December 2025. Legacy revenues were prominent in the earlier periods, but the contribution from alliance and royalty revenues increased over time, becoming a more substantial portion of the total revenue mix.

Profitability Analysis

Gross profit mirrored the revenue trends, increasing to US$19.094 billion in July 2022 before declining. Operating income demonstrated even more volatility, reaching a high of US$12.219 billion in July 2022, then falling to a loss of US$4.289 billion in December 2022. While operating income recovered somewhat in subsequent periods, it remained below the peak levels. Net income attributable to Pfizer Inc. common shareholders followed a similar pattern, with a peak of US$9.906 billion in July 2022 and a low of negative US$3.369 billion in December 2022. The final reported net income in December 2025 was negative US$1.647 billion.

Expense Management

Cost of sales generally tracked revenue, increasing with revenue growth and decreasing with revenue declines. Selling, informational, and administrative expenses remained relatively stable, fluctuating between approximately US$2.5 billion and US$4.6 billion. Research and development expenses also remained consistent, generally ranging between US$2.3 billion and US$3.2 billion. However, acquired in-process research and development expenses and restructuring charges exhibited significant variability, contributing to the overall volatility in operating income. Notably, acquired in-process research and development expenses were particularly high in September 2025, reaching US$1.390 billion.

Other Income and Taxes

Other income (deductions), net, fluctuated considerably throughout the period, sometimes offsetting losses and at other times exacerbating them. The provision for taxes on income also varied, shifting from a benefit to a provision depending on overall profitability. These factors contributed to the overall volatility in net income.

In summary, the period under review was characterized by substantial revenue and profit fluctuations. While initial growth was strong, performance declined significantly in late 2022 and remained volatile through the end of 2025. The increasing contribution of alliance and royalty revenues, coupled with fluctuating expenses and other income, shaped the overall financial results.